Condition (MeSH)
Long QT Syndrome
ClinicalTrials.gov lists 107 trials for Long QT Syndrome or a narrower condition beneath it. Gilead Sciences has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
101 of the 107 trials are tagged with Long QT Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Long QT Syndrome trials start? (26)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 9
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 5 |
| 2024 | 4 |
| 2023 | 7 |
| 2022 | 4 |
| 2021 | 7 |
| 2020 | 5 |
| 2019 | 7 |
| 2018 | 5 |
| 2017 | 4 |
Showing 10 of 26 earlier years.
No forecast is made for this condition: it averages 4.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 25 months across 67 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Long QT Syndrome trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 13 |
| Phase 1/2 | 1 |
| Phase 2 | 6 |
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Phase 4 | 5 |
| Not applicable | 22 |
| Observational | 58 |
How many Long QT Syndrome trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 13 |
| Enrolling by invitation | 4 |
| Active, not recruiting | 1 |
| Completed | 64 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Long QT Syndrome trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Gilead Sciences | 5 |
| Tel-Aviv Sourasky Medical Center | 3 |
| Thryv Therapeutics, Inc. | 3 |
Which drugs are being tested for Long QT Syndrome? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Eleclazine | 5 |
| Ibutilide | 4 |
| Ranolazine | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| C: moxifloxacin | 5 |
| Progesterone 8% | 4 |
| LQT-1213 | 2 |
| Testosteron | 2 |
| Ondansetron - Parts A + B | 2 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Long QT Syndrome trials report? (6)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Advanced Lead Extraction | 6 | 1 |
| Nephrolithiasis | 2 | 1 |
| Ventricular Fibrillation | 2 | 1 |
| Motor vehicle accident | 1 | 1 |
| Vertigo requiring discontinuation of therapy | 1 | 1 |
Showing 5 of 6 adverse events.
Which publications cover Long QT Syndrome? (412)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Concentration-QTc Analysis of Valemetostat in Patients With Hematologic Malignancies. | Clinical and translational science | 2025 | Yes |
| Concentration-Response Analysis of the Combination of Pyronaridine and Piperaquine on Corrected QT Interval From a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults of African Sub-Saharan Origin. | Clinical and translational science | 2025 | Yes |
| Cardiovascular Safety of Azithromycin in Patients Hospitalized With COVID-19: A Prespecified Pooled Analysis of the COALITION I and COALITION II Randomized Clinical Trials. | The American journal of cardiology | 2024 | Yes |
| QTc Interval Prolongation Is Independently Associated with FGF23 and Predicts Mortality in Predialysis Chronic Kidney Disease. | Cardiorenal medicine | 2024 | Yes |
| Effect on QTc interval by switching from methadone to equipotent R-methadone dose in methadone maintenance treatment patients. | Basic & clinical pharmacology & toxicology | 2024 | Yes |
Showing 5 of 412 publications.
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.